tickerreport.com
Positivewww.tickerreport.com ·
Dyne Therapeutics Nasdaqdyn CEO Sells 60789 96 in Stock
StewardInsiderNutritional ProgramsFood And In Kind Transfers
Topic context
Related topics
The full article is on the original publisher site.
AI insight
AI-generatedInsider sale for tax withholding is routine and not a commercial signal. No product, supply chain, or margin impact. No concrete commercial mechanism identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- CEO John Cox sold 3,311 shares on May 13, 2026 for $60,789.96 at $18.36/share.
- Sale was to cover tax withholding obligations related to equity awards.
- Cox retains 370,834 shares valued at ~$6.81 million (0.88% decrease).
- Dyne Therapeutics reported quarterly loss of $0.73 per share (vs consensus $0.77).
- Stock market cap $2.86 billion; 12-month range $8.06-$25.00.
Related stories
thehindubusinessline.com
Sensex Nifty50 Today Stock Market Highlights 9th June 2026
finanznachrichten.de
68718121 coforge limited coforge wins pega industry excellence award for government and public sector transformation work 004
proactiveinvestors.com
Ftse 100 Live London Blue Chips in the Red Gsk Deal Too Big for Some
stockhouse.com
Trilogy Metals Announces Commencement of 2026 Summer Field Program at the Upper
stockhouse.com